Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial

Benjamin A. Fisher, Tonny Veenith, Daniel Slade, Charlotte Gaskell, Matthew Rowland, Tony Whitehouse, James Scriven, Dhruv Parekh, Madhu Balasubramaniam, G Cooke, Nicholas Morley, Zoë Gabriel, Matt P. Wise, Joanna C. Porter, Helen McShane, Ling‐Pei Ho, Philip N. Newsome, Anna Rowe, Rowena Sharpe, David Thickett, Julian Bion, Simon Gates, Duncan Richards, Pamela Kearns, Bryan Williams, Rebecca Turner, Vincenzo Libri, Francis Mussai, Gary Middleton, S. Bowden, Mansoor N. Bangash, Fang Gao Smith, Jaimin Patel, Elizabeth Sapey, Mark R. Thomas, Mark Coles, Peter Watkinson, Naj Rahman, Brian Angus, Alexander J. Mentzer, Alex Novak, Marc D. Feldman, Alex Richter, Sian Faustini, Camilla Bathurst, Joseph Van de Wiel, Susie Mee, Karen James, Bushra Rahman, Turner, K, Hill, A, Gordon, A, Yap, C, Matthay, M, McAuley, D, Hall, A, Dark, P, McMichael, A